Published in J Clin Transl Hepatol on September 15, 2013
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Internal ribosome entry site within hepatitis C virus RNA. J Virol (1992) 9.14
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev (1998) 7.72
Epidemiology of hepatitis C virus infection. World J Gastroenterol (2007) 7.36
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Course and outcome of hepatitis C. Hepatology (2002) 6.51
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol (1993) 5.26
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol (1999) 4.37
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A (1999) 3.77
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol (1995) 3.41
The burden of hepatitis C in the United States. Hepatology (2002) 3.16
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure (1999) 3.04
Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol (2000) 2.89
Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology (2006) 2.87
Unscrambling hepatitis C virus-host interactions. Nature (2005) 2.83
Identification of hepatitis C virus NS5A inhibitors. J Virol (2010) 2.58
In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol (2003) 2.55
Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother (2010) 2.50
The La antigen binds 5' noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. Proc Natl Acad Sci U S A (1997) 2.43
American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology (2006) 2.39
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem (2004) 2.25
An enzymatic footprinting analysis of the interaction of 40S ribosomal subunits with the internal ribosomal entry site of hepatitis C virus. J Virol (2000) 2.21
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl (2006) 2.12
Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. J Virol (1998) 2.00
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95
Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol (2009) 1.92
Hepatitis C virus entry. J Biol Chem (2007) 1.91
A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol (2011) 1.91
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology (2011) 1.83
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology (2009) 1.82
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Structure and function of HCV IRES domains. Virus Res (2008) 1.81
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology (2009) 1.75
Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol (2001) 1.73
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Translation initiation by factor-independent binding of eukaryotic ribosomes to internal ribosomal entry sites. C R Biol (2005) 1.65
Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A (2008) 1.62
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem (2010) 1.58
Nuclear factors are involved in hepatitis C virus RNA replication. RNA (2007) 1.58
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother (2008) 1.56
Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J Biol Chem (2000) 1.54
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol (2007) 1.44
Host-directed drug targeting of factors hijacked by pathogens. Sci Signal (2008) 1.36
hnRNP C and polypyrimidine tract-binding protein specifically interact with the pyrimidine-rich region within the 3'NTR of the HCV RNA genome. Nucleic Acids Res (1999) 1.34
The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J Virol (2007) 1.32
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol (2012) 1.28
HCV drug discovery aimed at viral eradication. J Viral Hepat (2009) 1.19
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18
An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6, facilitate hepatitis C virus replication. J Virol (2007) 1.16
Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci U S A (2009) 1.14
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis (2010) 1.14
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol (2009) 1.11
Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A (2009) 1.11
The domains of polypyrimidine tract binding protein have distinct RNA structural preferences. Biochemistry (2009) 1.10
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
The emerging field of HCV drug resistance. Expert Opin Investig Drugs (2008) 1.05
Lower concentration of La protein required for internal ribosome entry on hepatitis C virus RNA than on poliovirus RNA. J Gen Virol (1999) 1.03
Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol (1998) 1.00
The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly. J Virol (2010) 1.00
The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol (2008) 0.98
A new era of hepatitis C therapy begins. N Engl J Med (2011) 0.97
Hepatic Sarcoidosis. J Clin Transl Hepatol (2013) 0.82
Hepatic Echinococcal Cysts: A Review. J Clin Transl Hepatol (2016) 0.82
Targeted transplantation of mitochondria to hepatocytes. Hepat Med (2016) 0.75
Secondary Structural Elements of the HCV X-region Involved in Viral Replication. J Clin Transl Hepatol (2015) 0.75
Thrombotic Venous Diseases of the Liver. J Clin Transl Hepatol (2015) 0.75
Occult HCV Infection (OCI) Diagnosis in Cirrhotic and Non-cirrhotic Naïve Patients by Intra-PBMC Nested Viral RNA PCR. J Clin Transl Hepatol (2017) 0.75
Found in Translation. J Clin Transl Hepatol (2013) 0.75
Mechanisms and Prevention of Vertical Transmission in Chronic Viral Hepatitis. J Clin Transl Hepatol (2017) 0.75